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Abstract
Background: Endometrial receptivity is one of the important factors in assisted
reproductive technology (ART) success. In the luteal phase of an ART cycle, serum
estradiol (E2) and progesterone are often placed in low levels. Supporting the luteal
phase with progesterone is a usual method.
Objective: To evaluate the effects of E2 supplementation plus progesterone on the
luteal phase support in the antagonist protocol who have undergone intracytoplasmic
sperm injection-embryo transfer cycles.
Materials and Methods: In this cross-sectional study, 200 patients with antagonist
stimulation protocol, who had undergone intracytoplasmic sperm injection treatment,
were divided into two groups based on the use of E2 supplementation. In both
groups, 400 mg progesterone suppositories (Cyclogest®), twice a day/vaginally, was
administered starting from the day of oocyte collection until the fetal heart activity.
However, in the E2 group, in addition to progesterone, 4 mg tablet of E2 was received
daily. Beta hCG was checked 14 days after the embryo transfer, and the clinical
pregnancy rate was the main endpoint.
Results: The patients’ characteristics were matched, and insignificant differences were
observed, except for endometrial thickness. The clinical outcomes showed the rate of
pregnancy was higher in the E2 group compared to the control group; nonetheless,
statistically, there was no noticeable difference.
Conclusion: E2 supplementation had no beneficial effect in the luteal phase support
of IVF cycles. Nevertheless, more studies are required to confirm the supportive role
of E2 supplementation for embryo implantation and to improve the outcomes in ART
cycles.
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1. Introduction
Assisted Reproductive Technology (ART)
has been used worldwide for many years and
embryo implantation is a main factor of this
program. Endometrial receptivity is one of the
important attributes in the success of ART
(1). During controlled ovarian hyperstimulation,
supraphysiologic levels of estradiol (E2) causes
a decrease in the luteinizing hormone levels,
following which the corpus luteum may be
inactivated in the absence of luteinizing hormone
(2). Unfortunately, the use of Gonadotropin-
releasing Hormone (GnRH) analogs also causes
the inhibition of corpus luteum in these cycles.
In addition, during oocyte retrieval, the granulosa
cells curettage, as a consequence of which
both corpus luteum function and progesterone
production decrease. In the luteal phase of an
ART cycle, serum E2 and progesterone often fall
too low levels (3). The incidence and maintenance
of pregnancy require suitable secretion of P from
the corpus luteum (4). Therefore, a progesterone
supplement is run during the luteal phase to
reach the ideal endometrial receptivity. There
are various protocols of luteal support in the
ART cycles. particularly, the luteal phase support
(LPS) with progesterone, as a usual method (2).
E2 plays an important role in the proliferation of
the epithelial, stromal, and uterine vessels in the
follicular phase of the menstrual cycle (5). Beckers
and coworkers showed that a mid-luteal decrease
of estrogen occurs following the luteal vaginal
bleeding, which may be related to implantation
failure (6). The benefit of additional LPS with E2
is not clear; some studies have found out that
the a co-administration of E2 with P in the luteal
phase increases the implantation and pregnancy
rates in the women who have undergone in
vitro fertilization/intracytoplasmic sperm injection-
embryo transfer (IVF/ICSI-ET) cycles, as compared
to progesterone alone (2).
The key objective of the present study was to
evaluate the effect of E2 supplementation plus to
progesterone for the LPS in antagonist protocol
on the clinical outcomes of patients who have
undergone ICSI-ET cycles.
2. Materials and Methods
2.1. Patients
In this cross-sectional study, 200 women
who referred to Yazd Research and Clinical
Center for Infertility during one year from
April 2018 to April 2019 were treated with
ICSI-ET with controlled ovarian stimulation by
antagonist protocol were selected. Among them,
only those who were in the Fresh embryo
transfer cycle were studied. According to
the LPS protocol, patients were divided into
two groups as a control group that received
progesterone alone and the E2 group which
received E2+progesterone.
Women with the risk of ovarian hyperstimulation
syndrome, history of endometriosis, surgical
hysteroscopy, having more than two implantation
procedures, and severe male factor were
excluded.
2.2. Treatment protocol
The stimulation protocol was started from
the second day of the cycle with injecting 150-
225 IU recombinant human follicle-stimulating
hormone (Gonal-F Serono or Pergoveris, Merck-
Serono, Germany) for five days. On the 6th day,
follicles size and medication response were
evaluated through transvaginal sonography.
After confirming the mature follicle (≥ 14 mm)
by transvaginal sonography, 0.25 mg/daily
GnRH antagonist (Cetrotide, Merck-Serono,
Germany) was injected subcutaneously. hCG
(5000-10000 IU) (Pregnyl, Organon, Netherland)
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was injected when at least two follicles with
a mean diameter of 17 mm were observed.
Oocyte pick up was done under sedation36 hr
after triggering. ICSI was done for all mature
oocytes.
Embryo transfers were performed with a
soft COOK Medical embryo transfer catheter
(COOK, USA) and ultrasound guidance on
the second day. Two good-quality embryos
(grade A, and B) were transferred. In both
groups, 400 mg of progesterone suppositories
(Cyclogest®, Barnstaple, UK) was started twice
a day from the day of oocyte retrieval and
continued until the detection of fetal heart
activity. However, in the E2 group, 2 mg oral
tablet of E2 valerate (Aburaihan Co., Tehran,
Iran), was given twice a day from the day of
embryo transfer and continued until the fetal heart
activity.
Chemical pregnancy was assessed by
measuring the serum beta-hCG (β-hCG) on
day 14 after the embryo transfer. A positive
pregnancy test was definitive when β-
hCG > 50 IU/L. Clinical pregnancies were
confirmed when fetal heart activity was
determined by transvaginal ultrasonography
2-3 wk after positive β-hCG. The implantation
rate was defined as the gestational sacs
to the number of the embryos transferred
ratio.
2.3. Ethical consideration
The study protocol was approved by
the ethics committee of the Research and
Clinical Center for Infertility, Yazd, Iran (Code:
IR.SSU.RSI.REC.1398.028). Written consent forms
were signed by all participants prior to the study.
2.4. Statistical analysis
Data were presented as Mean ± SD and
analyzed using the SPSS version 20 (Statistical
Package for the Social Sciences, SPSS, Chicago,
IL). The normality of data was checked with the
Shapiro test. Independent t test and Pearson’s Chi-
square test (χ2) were used to compare the groups.
P < 0.05 was considered as statistically significant.
3. Results
Results showed that there was no statistically
significant difference between groups except for
the endometrial thickness (p = 0.048) (Table I).
For each group, the patients were selected from
different etiologies and there was no difference
between them (Table II). In comparison of clinical
outcomes the results showed that the rate of
pregnancy was higher in E2 groups; however,
statistically, it was insignificant (Table III).
Table I. Comparison of patients’ characteristics between the two groups
Patients characteristics Estradiol group Control group P-value
Age 31.35 ± 4.66 31.03 ± 4.6 0.627
BMI 25.46 ± 2.93 23.36 ± 1.33 0.318
Duration infertility 5.9 ± 3.57 6.02 ± 3.21 0.797
AMH 2.29 ± 1.06 2.66 ± 1.5 0.196
Embryo 2.62 ± 1.31 2.87 ± 1.41 0.198
Num. embryo transfer 1.82 ± 0.38 1.79 ± 0.40 0.595
COC 6.72 ± 2.82 6.23 ± 2.39 0.187
MII 4.19 ± 1.96 4.05 ± 1.84 0.604
Estradiol 1017.8 ± 345.8 1054.5 ± 404.9 0.492
Endometrial thickness 9.05 ± 1.18 9.44 ± 1.34 0.048∗
Duration of stimulation 13 ± 1.93 13. 1 ± 2.00 0.051
Gonadotropin dose 2834071.5 ± 892655.34 2921067.0 ± 681763.18 0.440
Data presented as Mean ± SD. Independent t test and; *p-value < 0.05 was significant
AMH: Anti-mullerian hormone; COC: Cumulus oocyte complex; MII: Metaphase II; BMI: Body mass index
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Table II. Comparison of different etiologies between groups
Variables MF PCO OF TF Unknown Mixed P-value
Estradiol group 29 (29) 9 (9) 21 (21) 4 (4) 20 (20) 17 (17)
Control group 28 (28) 13 (13) 24 (24) 1 (1) 18 (18) 16 (16)
0.718
Data presented as percentage. Chi-square test, MF: Male factor; PCO: Polycystic ovary; OF: Ovarian factor; TF: Tubal factor
Table III. Comparison of pregnancy outcomes between the two groups
Variables Estradiol group (n = 100) Control group (n = 100) OR (CI) P-value
Chemical pregnancy 33 (33) 28 (28) 1.26 (0.69-2.31) 0.539
Clinical pregnancy 26 (26) 21 (21) 1.32 (0.68-2.54) 0.505
Data presented as percentage. Chi-square test, OR: Odds ratio; CI: Confidence interval
4. Discussion
The result of this study showed that endometrial
thickness was statistically different between the
groups that according to our previous study this
difference was negligible (7). In the present study,
we aimed to compare the efficacy of adding E2
to progesterone in LPS in antagonist protocols
and evaluate ICSI outcomes. The results showed
that a co-administration of progesterone and
E2 in the luteal phase had a similar result as
with only progesterone supplementation. While
several studies have evaluated the effect of LPS of
estrogen supplementation on the pregnancy rate,
it is still a debated matter (3, 5, 8). Some studies
assessed the effect of estrogen supplementation
on agonist IVF cycles (9). However, in antagonist
IVF cycles, it is still a debate. Drakakis and
coworkers evaluated the effect of E2 in the luteal
phase in ICSI patients and reported that E2 not
only had a positive effect on the pregnancy
outcome but also has no adverse effects (10). Also,
Zhang and colleague in a systematic review and
meta-analysis showed a higher clinical pregnancy
rate (CPR) in progesterone plus estrogen for
LPS compare to progesterone alone in IVF
cycles (11). In contrast, Huang and colleagues
in a meta-analysis stated that oral estrogens
supplementation for luteal phase in agonist IVF
cycles did not improve the IVF/ICSI outcomes
(3).
Some studies concluded that there was no
benefit of adding E2 similar to our study (8,
12-15). Çakar and coworker evaluated patients
in the ICSI cycles and the antagonist protocol.
Progesterone 90 mg vaginal gel once a day
and micronized E2 4 mg/day were started from
the day of oocyte collection and continued till
the 12th day of embryo transfer. They revealed
that the addition of E2 to LPS had no valuable
outcome on CPR in antagonist IVF cycles (8).
Munjal and coworker, in a group of women who
had undergone the controlled ovarian stimulation
by gonadotropin and GnRH antagonist protocol,
determined that giving E2 supplementation along
with progesterone in the luteal phase did not
improve the pregnancy rates significantly (13).
Ismail Madkour and colleagues also reported
similar outcome and concluded that the daily
addition of 4 mg estrogen for luteal support in
ART cycle, using the antagonist protocol, did
not increase the pregnancy outcomes (16). The
effect of adding E2 in the luteal phase may
be dose-dependent. Lukaszuk and colleagues
confirmed a meaningfully higher CPR in a group
accompanied with 6 mg E2 compared to a group
complemented with 2mg E2 and the group without
E2 (17).
Page 972 https://doi.org/10.18502/ijrm.v13i11.7964
International Journal of Reproductive BioMedicine Estradiol as a luteal support and pregnancy
A few previous studies have considered whether
or not E2 supplementation is useful in patients with
different ovarian responses and serum E2 levels
(3, 10). Zhao and co-workers in a retrospective
cohort study concluded that the effects of adding
E2 for luteal phase depended on the E2 levels
on the hCG trigger day. E2 supplementation was
linked to improved outcomes in patients with low
E2 levels; however, it was harmful in persons
with high E2 levels on the trigger day. They
presented that E2 supplementation in cases with
E2 < 5,000 pmol/L on the day of hCG trigger
considerably increased their live birth rate (4).
Kasapoglu and colleague assessed the clinical
outcomes of patients who had a ratio of serum
E2 levels to the oocytes number < 100 pg/ml
and received E2 supplementation during the luteal
phase. They concluded that implantation and CPR
per embryo transfer following the transfer of a
single embryo did not increase after addition of
E2 in the luteal phase (18). On the other hand,
Kutlusoy and colleagues evaluated this program
(E2 + progestin) in IVF cycles with poor responder
patients. They showed that adding 2 mg/day E2
in addition to P for luteal support meaningfully
increased CPRs in such patients (19).
5. Conclusion
In conclusion, the supportive role of E2 in
improving embryo implantation and pregnancy is
unclear and needs further studies. Although the
results of this study exhibited no useful effect of E2
supplementation in the luteal phase of IVF cycles,
estrogen supplementation may be useful in some
subgroups of the patients. Therefore, a large RCT
study is needed to further clear up the role of luteal
E2 supplementation in IVF cycles, as well as the
optimal regimen (dose and route), not well defined
to the date.
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